iADRS (Integrated Alzheimer's Disease Rating Scale)
Neurology· appears in 97+ cited findings in this library
What it is and how the reviews use it
The Integrated Alzheimer's Disease Rating Scale (iADRS) is an endpoint used in regulatory reviews for Alzheimer's disease treatments. The iADRS score ranges from 0 to 144, as defined in the Eli Lilly and Company — Kisunla FDA Review (BLA761248, ORIG 1, 2024) on page 32. This scale is designed to measure the overall impact of Alzheimer's disease.
Regulatory reviews in this library utilize iADRS to assess treatment efficacy. For instance, the Eli Lilly and Company — Kisunla EMA EPAR public assessment report (EME, p.147) noted an iADRS ≥13.5 point decrease HR (overall population) of 0.702. The Eli Lilly and Company — Kisunla FDA Review (BLA761248, ORIG 1, 2024) on page 48 reported an iADRS change from baseline of -22.3%. Additionally, the EISAI INC — Leqembi FDA Review (NDA/BLA 761269, 2024) on page 163 showed a modified iADRS percent difference vs. placebo (FAS+ population) of -30%.
Real examples — cited to the source page
| Kisunla | iADRS ≥13.5 point decrease HR (overall population) | 0.702 | Eli Lilly and Company — Kisunla EMA EPAR public assessment report, p.147 |
| Kisunla | iADRS change from baseline | -22.3% | Eli Lilly and Company — Kisunla FDA Review, p.48 |
| Leqembi | modified iADRS percent difference vs. placebo (FAS+ population) | -30% | EISAI INC — Leqembi FDA Review, p.163 |
Different drugs were studied in different trials — these values are not head-to-head comparisons.
Explore the full evidence
Every iADRS finding in the library — searchable and answerable in plain language — is in the Neurology research library →
Figures are as stated in the cited source documents. Educational reference only — not medical or investment advice.